Segui
Catrin Plumpton
Catrin Plumpton
Email verificata su bangor.ac.uk
Titolo
Citata da
Citata da
Anno
Random subspace ensembles for fMRI classification
LI Kuncheva, JJ Rodríguez, CO Plumpton, DEJ Linden, SJ Johnston
IEEE transactions on medical imaging 29 (2), 531-542, 2010
2842010
A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions
CO Plumpton, D Roberts, M Pirmohamed, DA Hughes
Pharmacoeconomics 34, 771-793, 2016
1612016
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non …
A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ...
The Lancet 397 (10282), 1375-1386, 2021
1572021
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority …
A Marson, G Burnside, R Appleton, D Smith, JP Leach, G Sills, ...
The Lancet 397 (10282), 1363-1374, 2021
1532021
Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey
VL Morrison, EAF Holmes, S Parveen, CO Plumpton, W Clyne, ...
Value in Health 18 (2), 206-216, 2015
1302015
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron …
P Ghaneh, R Hanson, A Titman, G Lancaster, C Plumpton, ...
Health Technology Assessment 22 (7), 2018
1052018
Multiple imputation of multiple multi-item scales when a full imputation model is infeasible
CO Plumpton, T Morris, DA Hughes, IR White
BMC research notes 9, 1-15, 2016
782016
Cost‐effectiveness of screening for HLA‐A*31:01 prior to initiation of carbamazepine in epilepsy
CO Plumpton, VLM Yip, A Alfirevic, AG Marson, M Pirmohamed, ...
Epilepsia 56 (4), 556-563, 2015
692015
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
CO Plumpton, A Alfirevic, M Pirmohamed, DA Hughes
Rheumatology 56 (10), 1729-1739, 2017
572017
Conducting economic evaluations alongside randomised trials: current methodological issues and novel approaches
D Hughes, J Charles, D Dawoud, RT Edwards, E Holmes, C Jones, ...
Pharmacoeconomics 34, 447-461, 2016
562016
The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey
NJ Hulbert‐Williams, CO Plumpton, P Flowers, R McHugh, RD Neal, ...
European journal of cancer care 26 (4), e12670, 2017
542017
Linear mixed models to handle missing at random data in trial‐based economic evaluations
A Gabrio, C Plumpton, S Banerjee, B Leurent
Health Economics 31 (6), 1276-1287, 2022
472022
Naive random subspace ensemble with linear classifiers for real-time classification of fMRI data
CO Plumpton, LI Kuncheva, NN Oosterhof, SJ Johnston
Pattern Recognition 45 (6), 2101-2108, 2012
472012
Adaptive learning rate for online linear discriminant classifiers
LI Kuncheva, CO Plumpton
Structural, Syntactic, and Statistical Pattern Recognition: Joint IAPR …, 2008
472008
Societal preferences for funding orphan drugs in the United Kingdom: an application of person trade-off and discrete choice experiment methods
SM Bourke, CO Plumpton, DA Hughes
Value in Health 21 (5), 538-546, 2018
452018
Attitudes towards epilepsy in the UK population: results from a 2018 national survey
E Holmes, S Bourke, C Plumpton
Seizure 65, 12-19, 2019
442019
Choosing parameters for random subspace ensembles for fMRI classification
LI Kuncheva, CO Plumpton
International workshop on multiple classifier systems, 54-63, 2010
362010
Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
AV Ramanan, AD Dick, AP Jones, DA Hughes, A McKay, A Rosala-Hallas, ...
Health Technology Assessment (Winchester, England) 23 (15), 1, 2019
322019
Cost‐effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: An evaluation framework
CO Plumpton, M Pirmohamed, DA Hughes
Clinical Pharmacology & Therapeutics 105 (6), 1429-1438, 2019
312019
Patient‐Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs
EAF Holmes, C Plumpton, GA Baker, A Jacoby, A Ring, P Williamson, ...
Clinical Pharmacology & Therapeutics 105 (3), 672-683, 2019
302019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20